Literature DB >> 16998683

Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Won-Suk Lee1, Kwang-Woong Lee, Jin-Seok Heo, Sung-Ju Kim, Seong-Ho Choi, Yong-Il Kim, Jae-Won Joh.   

Abstract

PURPOSE: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary hepatic neoplasm (PHN) with features of both hepatocellular and biliary differentiation. We compared the outcome of hepatic resection in patients with HCC-CC, those with hepatocellular carcinoma (HCC), and those with cholangiocarcinoma (ICC).
METHODS: Between November 1994 and December 2003, 952 patients underwent hepatic resection for a PHN.
RESULTS: The incidence of HCC-CC was 3.5%. Hepatitis B surface antigen was positive in 51.2% of these patients and the HCV antibody was positive in 12.2%. Positive hepatitis serology was more common in the HCC group (66.7%). The prevalence of underlying liver cirrhosis was significantly lower in the ICC group (7.8%) than in the HCC (49%) and HCC-CC (41.5%) groups (P < 0.0001). The median overall survival periods after hepatic resection of HCC-CC, HCC, and ICC were 47.3, 71.7, and 21.5 months, respectively (P < 0.0001). The median disease-free survival (DFS) periods after hepatic resection for HCC-CC, HCC, and ICC were 23.4, 68.2, and 15.5 months, respectively (P < 0.0001).
CONCLUSION: Patients with transitional type HCC-CC had significantly poorer survival rates than those with HCC, after hepatic resection. Therefore, a more aggressive treatment modality should be explored to improve the survival rate of these patients.

Entities:  

Mesh:

Year:  2006        PMID: 16998683     DOI: 10.1007/s00595-006-3276-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  9 in total

1.  Combined liver cell and bile duct carcinoma.

Authors:  R A ALLEN; J R LISA
Journal:  Am J Pathol       Date:  1949-07       Impact factor: 4.307

2.  Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features.

Authors:  T Maeda; E Adachi; K Kajiyama; K Sugimachi; M Tsuneyoshi
Journal:  Hum Pathol       Date:  1995-09       Impact factor: 3.466

3.  Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study.

Authors:  Z D Goodman; K G Ishak; J M Langloss; I A Sesterhenn; L Rabin
Journal:  Cancer       Date:  1985-01-01       Impact factor: 6.860

4.  A clinicopathological study on combined hepatocellular and cholangiocarcinoma.

Authors:  J Taguchi; O Nakashima; M Tanaka; T Hisaka; T Takazawa; M Kojiro
Journal:  J Gastroenterol Hepatol       Date:  1996-08       Impact factor: 4.029

5.  Combined hepatocellular-cholangiocarcinoma: a clinicopathological study.

Authors:  I O Ng; T W Shek; J Nicholls; L T Ma
Journal:  J Gastroenterol Hepatol       Date:  1998-01       Impact factor: 4.029

6.  Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors.

Authors:  William R Jarnagin; Sharon Weber; Satish K Tickoo; Jonathan B Koea; Sam Obiekwe; Yuman Fong; Ronald P DeMatteo; Leslie H Blumgart; David Klimstra
Journal:  Cancer       Date:  2002-04-01       Impact factor: 6.860

7.  Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan.

Authors:  M Tomimatsu; N Ishiguro; M Taniai; H Okuda; A Saito; H Obata; M Yamamoto; K Takasaki; M Nakano
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

8.  Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.

Authors:  Yoshiko Yano; Junji Yamamoto; Tomoo Kosuge; Yoshihiro Sakamoto; Susumu Yamasaki; Kazuaki Shimada; Hidenori Ojima; Michiie Sakamoto; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Jpn J Clin Oncol       Date:  2003-06       Impact factor: 3.019

9.  Hepatic resection for combined hepatocellular and cholangiocarcinoma.

Authors:  Chi-Leung Liu; Sheung-Tat Fan; Chung-Mau Lo; Irene Oi-Lin Ng; Chi-Ming Lam; Ronnie Tung-Ping Poon; John Wong
Journal:  Arch Surg       Date:  2003-01
  9 in total
  41 in total

1.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.

Authors:  Mitsumaro Itoyama; Masaki Hata; Koji Yamanegi; Naoko Yamada; Hideki Ohyama; Hiroshi Hirano; Nobuyuki Terada; Keiji Nakasho
Journal:  Med Mol Morphol       Date:  2012-03-20       Impact factor: 2.309

3.  Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma.

Authors:  Chae Hong Lim; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee; Seung Hyup Hyun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-02       Impact factor: 9.236

4.  Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?

Authors:  Ijin Joo; Jeong Min Lee; Dong Ho Lee; Ju Hyeon Jeon; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-03-14       Impact factor: 5.315

Review 5.  Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review.

Authors:  Damiano Gentile; Matteo Donadon; Ana Lleo; Alessio Aghemo; Massimo Roncalli; Luca di Tommaso; Guido Torzilli
Journal:  Liver Cancer       Date:  2019-11-01       Impact factor: 11.740

6.  Impact of operative and peri-operative factors on the long-term prognosis of primary liver cancer patients undergoing hepatectomy.

Authors:  Li-Ning Xu; Ying-Ying Xu; De-Wei Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

7.  Combined hepatocellular and cholangiocellular carcinoma presenting with radiological characteristics of focal nodular hyperplasia.

Authors:  Inneke Willekens; Anne Hoorens; Caroline Geers; Bart Op de Beeck; Frederik Vandenbroucke; Johan de Mey
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

8.  Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis.

Authors:  Hyun Jeong Park; Kyung Mi Jang; Tae Wook Kang; Kyoung Doo Song; Seong Hyun Kim; Young Kon Kim; Dong Ik Cha; Joungyoun Kim; Juna Goo
Journal:  Eur Radiol       Date:  2015-12-03       Impact factor: 5.315

9.  Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features.

Authors:  Hyungjin Rhee; Chansik An; Hye-Young Kim; Jeong Eun Yoo; Young Nyun Park; Myeong-Jin Kim
Journal:  Liver Cancer       Date:  2018-05-15       Impact factor: 11.740

10.  JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma.

Authors:  Qingshan Chang; Jianguo Chen; Kevin J Beezhold; Vince Castranova; Xianglin Shi; Fei Chen
Journal:  Mol Cancer       Date:  2009-08-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.